We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · October 21, 2019

Efficacy and Safety of the Oral JAK1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis

JAMA Dermatology


Additional Info

JAMA Dermatology
Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial
JAMA Dermatol 2019 Oct 02;[EPub Ahead of Print], MJ Gooderham, SB Forman, R Bissonnette, JS Beebe, W Zhang, C Banfield, L Zhu, J Papacharalambous, MS Vincent, E Peeva

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading